Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.

ABSTRACT:

Background

This trial evaluated the efficacy and safety of anti-programmed cell death 1 antibody (SCT-I10A) and anti-epidermal growth factor receptor (EGFR) antibody (SCT200) in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC) (trial registration number: NCT04229537).

Methods

This multicenter, open-label, phase 1b clinical trial enrolled patients with advanced ESCC refractory or intolerant to standard chemotherapy. Patients who had not received prior treatment with programmed death-(ligand)1 (PD-(L)1) immune checkpoint inhibitors (ICIs) or anti-EGFR antibodies comprised cohort 1A, and those who had previously failed treatment with PD-(L)1 ICIs or anti-EGFR antibodies comprised cohort 1B. Eligible patients were treated with SCT200 and SCT-I1

SUBMITTER: Bai M 

PROVIDER: S-EPMC12358056 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature